Advancing Epigenetics Towards Systems Biology

Epigenesys activities

EpiGeneSys is delighted to introduce 11 new RISE1 members for 2012!

Monday 01 October 2012 - Monday 01 October 2012



guillaume filionGuillaume Filion - Centre de Regulació Genòmica (CRG), Barcelona, Spain

Guillaume is the principal investigator of the team Genome Architecture. The main focus of their work is to decode the non coding genome and understand how the cells know what to do with it.


jonathan houselyJonathan Houseley - The Babraham Institute, Cambridge, United Kingdom

Jonathan's group is investigating how non-coding RNAs remodel the genome and the epigenome, and what impacts histone modifications and DNA rearrangements have on gene expression.


reini lucoReini F. Luco, Institut de Génétique Humaine, Montpellier , France

Reini discovered the world of epigenetics during her PhD in Barcelona, where she started studying different aspects of gene expression regulation by histone modifications. It still amazes her that the same modifications can regulate so many different layers of gene regulation in such an integrated way, from transcription to nuclear gene repositioning and now even alternative splicing.


manolis papamichosManolis Papamichos-Chronakis, Institut Curie, Paris, France

Manolis graduated from University of Crete/IMBB in Greece and did his postdoc in UMass Medical School, USA. In 2010, he established his team in the unit of Nuclear Dynamics and Genome Plasticity of the Insyitut Curie, focusing his research on the role of chromatin remodeling enzymes and histone variants in genome stability.


claire rougeulleClaire Rougeulle - CNRS / Université Paris Diderot, Paris, France

Claire's career has focused on epigenetic mechanisms and on the role of long non-coding RNAs (ncRNAs). In particula, her lab is investigating how these non-coding partners are controlling epigenetic processes in the context of stem cells and their extraordinary plasticity, using X-inactivation as a paradigm. They also aim to explore how the environment can impact these processes and thus affect cell fate.


peter rugg-gunnPeter Rugg-Gunn - The Babraham Institute, Cambridge, United Kingdom

The focus of Peter's research is to understand how the epigenome is modulated during stem cell differentiation and reprogramming and also how this can affect cell fate decisions during early mammalian development.


yuri schwartzYuri Schwartz - Umeå University, Sweden

Yuri is a Drosophila geneticist by training but his research interests revolve around mechanisms that control heritable programming of genome expression. His current focus is on the regulatory elements that attenuate gene expression via altering their position within the cell nucleus and on epigenetic regulation of transcription at a chromatin level.


nicole soranzoNicole Soranzo - Wellcome Trust Sanger Institute, Hinxton, United Kingdom

Nicole is a human geneticist, her research focuses on the study of genetic influences on quantitative variation in human populations, with a particular emphasis on complex cardiometabolic endpoints and disease.


vijay tiwariVijay Tiwari - Institute of Molecular Biology (IMB), Mainz, Germany

Vijay's research is aimed at achieving an integrated molecular and systems-level understanding of the mechanisms by which epigenetic mechanisms contribute to transcriptional reprogramming during cellular differentiation and how this communication is altered in diseases such as cancer.


juan vaquerizasJuan M. Vaquerizas, Max Planck Institute for Molecular Biomedicine, Münster, Germany

Juanma's laboratory is focused on understanding different aspects of epigenetics and transcriptional regulation such as chromatin organisation and nuclear architecture, or mono-allelic gene expression, all from a genome-wide perspective.


michiel vermeulenMichiel Vermeulen - University Medical Center Utrecht, The Netherlands

Michiel was trained as a biochemist and his research focus has always been the field of epigenetics. In recent years he has acquired expertise in quantitative mass spectrometry based proteomics technology and is currently applying this technology to answer questions in the field of epigenetics, with a particular focus on development and cancer.